Zomedica Corp. (ZOM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZOM POWR Grades
- ZOM scores best on the Growth dimension, with a Growth rank ahead of 67.27% of US stocks.
- The strongest trend for ZOM is in Stability, which has been heading down over the past 40 weeks.
- ZOM ranks lowest in Stability; there it ranks in the 1st percentile.
ZOM Stock Summary
- With a price/sales ratio of 16,757.6, Zomedica Corp has a higher such ratio than 99.76% of stocks in our set.
- As for revenue growth, note that ZOM's revenue has grown 111.11% over the past 12 months; that beats the revenue growth of 94.05% of US companies in our set.
- In terms of volatility of its share price, ZOM is more volatile than 98.7% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Zomedica Corp, a group of peers worth examining would be URG, CVM, TFFP, CALT, and MRSN.
- Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.
ZOM Valuation Summary
- ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
Below are key valuation metrics over time for ZOM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZOM | 2021-08-31 | 20836.7 | 2.3 | -34.9 | -19.6 |
| ZOM | 2021-08-30 | 20216.7 | 2.2 | -33.9 | -18.5 |
| ZOM | 2021-08-27 | 20640.0 | 2.2 | -34.6 | -19.2 |
| ZOM | 2021-08-26 | 22533.3 | 2.4 | -37.8 | -22.4 |
| ZOM | 2021-08-25 | 18940.0 | 2.1 | -31.7 | -16.4 |
| ZOM | 2021-08-24 | 16623.3 | 1.8 | -27.9 | -12.5 |
ZOM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZOM has a Quality Grade of F, ranking ahead of 3.96% of graded US stocks.
- ZOM's asset turnover comes in at 0 -- ranking 441st of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZOM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | -0.393 | -5.936 |
| 2021-03-31 | 0 | 0.599 | -5.609 |
| 2020-12-31 | 0 | NA | -5.395 |
| 2020-09-30 | 0 | NA | -6.260 |
| 2020-06-30 | 0 | NA | -6.329 |
| 2020-03-31 | 0 | NA | -5.504 |
ZOM Stock Price Chart Interactive Chart >
ZOM Price/Volume Stats
| Current price | $0.50 | 52-week high | $2.91 |
| Prev. close | $0.51 | 52-week low | $0.06 |
| Day low | $0.50 | Volume | 22,105,100 |
| Day high | $0.51 | Avg. volume | 77,900,688 |
| 50-day MA | $0.53 | Dividend yield | N/A |
| 200-day MA | $1.01 | Market Cap | 488.88M |
Zomedica Corp. (ZOM) Company Bio
Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.
Latest ZOM News From Around the Web
Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.
Zomedica Stock Will Need More Than a Change in Management to Bounce BackWhile a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock. |
New CEO and Acquisition Could Breathe New Life Into ZomedicaA turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business. |
Zomedica Has Potential, but It’s Far Too Expensive for NowZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play. |
The Challenges for Zomedica Continue, But It Still Has Huge PotentialCautious investors may want to hold off, as no matter what direction it goes (higher or lower), it'll do so in a big way. |
You Don’t Need a Short Squeeze To Enjoy Lemonade StockFor exposure to the future of insurance technology -- and a novel, pet-centered preventative care package -- give LMND stock a try. |
ZOM Price Returns
| 1-mo | -3.10% |
| 3-mo | -20.36% |
| 6-mo | -46.99% |
| 1-year | 553.59% |
| 3-year | -69.70% |
| 5-year | -52.19% |
| YTD | 116.83% |
| 2020 | -30.33% |
| 2019 | -73.09% |
| 2018 | -37.88% |
| 2017 | 91.99% |
| 2016 | N/A |
Loading social stream, please wait...